Phase 2 N=105 Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Chronic Rhinosinusitis
Primary: Change From Baseline in Nasal Polyp Score (NPS) to Week 16 — -0.87; -0.89; -0.49 score on a scale — p=0.2364
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=11 Healing Rate of Leg Wounds Treated With Contact and Noncontact Ultrasound: The VIP Ultrasound Protocol
Chronic Ulcer of Lower Extremity
Primary: Total Wound Area — 7.93125; 7.93125; 1.3275; 8.80875 Squared centimiters
N/A N=1,000 5 Year Observation of Patients With PORTICO Valves
Aortic Valve Stenosis
Primary: Percentage of Participants With All-cause Mortality — 12.1 percentage of participants
Phase 3 N=2,023 Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)
Rheumatoid Arthritis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 1760; 98; 617; 27 Participants
Phase 2 N=104 Intravenous Exenatide (Byetta) During Surgery
Euglycemia · Hypoglycemia · Hyperglycemia
Primary: The Primary Objective is to Determine the Ability of Intravenous Exenatide to: Maintain Intraoperative Euglycemia in Subjects With Initial Blood Glucose < 126 mg/dL in…
N/A N=78 Evaluation of a Daily Disposable Novel Multifocal Contact Lens in a Hyperopic Population
Visual Acuity
Primary: Binocular Visual Acuity (logMAR) — -0.07; -0.05; -0.05; -0.04 logMAR
Phase 2 N=83 Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: Best Corrected Visual Acuity (BCVA) — 3.9; 1.3; 2.6 Letters correct — p=0.582
Phase 2 N=25 Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens
Multiple Myeloma
Primary: Overall Response Rate (PR or Better) of Vorinostat in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory MM Refractory to a Previous…
Phase 2 N=43 Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
Multiple Myeloma
Primary: Percentage of Participants With Progression-Free Survival — 65.3; 72.7; 55.3; 59.1 percentage of participants — p=1.0
Phase 4 N=39 Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children
Appendicitis
Primary: Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale - Parent — 91.3; 90.2 score on a scale
N/A N=397 Online Information and Support for Distance Caregivers
Advanced Cancer
Primary: Change in Anxiety T-scores — 53.14; 55.47; 56.85 T-score — p=0.162
N/A N=16 Effects of rTMS on Brain Activation in Aphasia
Aphasia, Acquired
Primary: Change in Philadelphia Naming Test (PNT) Performance — 122.125; 130.875; 132.5; 142.125 Score on a scale
Phase 2 N=58 Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma AJCC v7
Primary: Objective Response Rate — 7; 0 percentage of participants
N/A N=80 Use of a New Stapling Device in General Thoracic Surgery
Thoracic Cancer
Primary: Number of Participants With Product Malfunction — 0 Participants
Phase 3 N=18 Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes
Type 1 Diabetes
Primary: Insulin Sensitivity: M-value From Hyperinsulinemic Euglycemia Clamp Study — 4.65; 3.67; 8.8; 9.05 mg/kg*minute*microIU/mL*100